Clinical trials
Liver Cancer (Locally Advanced or Metastatic) clinical trials
Below are recruiting liver cancer (locally advanced or metastatic) clinical trials, each written for real people, not researchers. We’re tracking 5,775 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07649070RecruitingPhase 2
Virus therapy and low-dose radiation for children with aggressive brain cancer
This trial tests whether a special herpes virus (G207) combined with low-dose radiation can help children with high-grade brain tumors (gliomas). The virus is injected into the tumor to attack the cancer cells while radiation helps boost the effect.
Houston, TexasAges 3–21 - NCT07646639RecruitingPhase 2
Radiation, chemotherapy, and immunotherapy for advanced rectal cancer
This study tests a combination of radiation therapy, chemotherapy drugs (capecitabine and oxaliplatin), and two types of immunotherapy (a PD-1 blocker and IL-2) for locally advanced rectal cancer. The goal is to see if this combination helps shrink tumors and improve outcomes before surgery.
Nanjing, JiangsuAges 18–70 - NCT05919030RecruitingPhase 3
Tislelizumab with chemoradiation for advanced esophagus cancer
This trial tests whether adding tislelizumab to chemoradiation as the first treatment helps people with advanced esophageal squamous cell cancer. It aims to improve how well the cancer responds when it cannot be cured with surgery or full-dose curative treatment.
Wuhan, HubeiAges 18 years+ - NCT06601335RecruitingPhase 3
New immunotherapy combo for head and neck cancer
This trial tests a new combination of two immunotherapy drugs (AK112 and AK117) versus the standard immunotherapy pembrolizumab for people with advanced head and neck cancer that hasn't been treated before.
Wuhan, HubeiAges 18–75 - NCT07644559RecruitingPhase 2
Study of VS-7375 with cetuximab for advanced pancreatic cancer
This trial tests a new drug combination for people with a specific KRAS mutation in pancreatic cancer. It aims to see if the treatment can shrink tumors or slow the disease.
Los Angeles, CaliforniaAges 18 years+ - NCT07639047RecruitingPhase 1
Testing AN8025 in Advanced Solid Cancers
This early-stage trial tests a new drug called AN8025 in people with advanced solid tumors (cancers that started in organs or tissues). The study aims to find the right dose and see if it helps patients whose cancers have grown despite other treatments.
Nedlands, Western AustraliaAges 18 years+ - NCT07644585Recruiting
Ultra-High Dose Rate Radiation for Recurrent Head and Neck Cancer
This trial tests a new type of radiation therapy called ConformalFLASH that delivers radiation extremely quickly to treat head and neck cancer that has come back after previous radiation. It may help patients who cannot have surgery or have declined it.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07644650RecruitingPhase 1
Study of MST-168 for advanced solid tumors
This study tests a new drug called MST-168 for people with advanced solid tumors (cancers that have spread or can't be removed). It aims to find out if the drug is safe and effective, and how the body handles it, which could lead to a new treatment option for those who have run out of standard options.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07638852RecruitingPhase 2
Combining radiation and targeted drugs for triple-negative breast cancer brain tumors
This trial is testing whether giving radiation therapy along with a combination of chemotherapy (cisplatin or carboplatin), an immunotherapy drug called adebrelimab, and a drug called bevacizumab can better treat triple-negative breast cancer that has spread to the brain. The goal is to see if this combination can shrink or control the brain tumors and improve outcomes.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05554003RecruitingPhase 2
Low-grade neuroendocrine tumors: metronomic temozolomide for frail patients
This Phase 2 study tests a gentler, steady schedule of temozolomide in people with advanced low-grade neuroendocrine neoplasms who are “unfit” for stronger treatments. The goal is to shrink or control the cancer while being safer for people with weaker health or organ function.
MilanAges 18 years+ - NCT07631793RecruitingPhase 1
Experimental vaccine for advanced solid tumors
This trial tests an experimental vaccine called YKYY031 for people with advanced solid tumors that have stopped responding to standard treatments. The vaccine aims to help your immune system fight cancer cells that carry specific markers. It may be an option if you have certain genetic markers and tumor proteins.
Beijing, Beijing MunicipalityAges 18–75 - NCT07632586Recruiting
First-in-Human Heart Pump Implant Study
This trial tests a new tiny heart pump called the Icoms Flowmaker for patients with severe heart failure who cannot have a standard heart pump. The device may help your heart pump blood better and improve your ability to do daily activities.
PragueAges 18–80 - NCT06222957Recruiting
How HER2 affects brown fat in breast cancer patients
This study looks at how a protein called HER2 affects brown fat activity in women with breast cancer. Brown fat helps burn calories and may influence treatment outcomes. You will be assigned to one of two groups based on your cancer's HER2 status, and the study will measure how your brown fat responds to cold.
CopenhagenAges 18 years+ - NCT07621614RecruitingPhase 2
Safe Surgery Guidance for Childhood Melanoma Using Genetics
This study helps doctors decide the safest surgical approach for melanoma and similar skin tumors in children and young adults by using pathology reports and genetic information. The goal is to avoid unnecessary surgery while ensuring the best outcomes.
Oakland, CaliforniaAges Up to 25 years - NCT06692725Recruiting
Lighter chemo with immunotherapy for triple-negative breast cancer
This trial tests whether using less chemotherapy combined with immunotherapy before surgery works well for people with stage II or III triple-negative breast cancer. The goal is to reduce side effects while still being effective.
Beijing, Beijing MunicipalityAges Any age - NCT07624487RecruitingPhase 2
Aumolertinib and chemotherapy for EGFR L858R lung cancer
This trial tests a combination of aumolertinib (a targeted cancer drug) with chemotherapy in patients with advanced lung adenocarcinoma that has a specific genetic mutation called EGFR L858R. The goal is to see if this combination can slow or shrink the cancer better than existing treatments.
New Taipei CityAges 18 years+ - NCT06702826RecruitingPhase 2
Cadonilimab plus radiation for lung cancer brain mets
This trial tests a combination of a targeted immunotherapy drug (cadonilimab) with a precise type of radiation to treat brain tumors that have grown after initial lung cancer treatment. The goal is to see if this approach can safely shrink brain metastases and improve outcomes.
Changsha, HunanAges 18–75 - NCT06700369Recruiting
Lowering chemo with targeted therapy for HER2+ breast cancer
This study looks at whether using targeted therapy can reduce the amount of chemotherapy needed before surgery for HER2-positive breast cancer. It aims to find a safer, equally effective treatment plan.
Beijing, Beijing MunicipalityAges Any age - NCT07615049RecruitingPhase 3
Shorter versus standard radiation for soft tissue sarcoma
This trial compares a shorter course of radiation therapy with the standard longer course for people with soft tissue sarcoma in an arm or leg. The goal is to see if the shorter course works just as well and may be more convenient.
Birmingham, AlabamaAges 18 years+ - NCT06700382Recruiting
Capecitabine for TNBC after incomplete response
This trial looks at different ways to use the chemotherapy drug capecitabine for people with triple-negative breast cancer who still have cancer cells after initial treatment and surgery. It aims to find the best approach to improve outcomes.
Beijing, Beijing MunicipalityAges Any age - NCT05667194RecruitingPhase 1
Early study of KH617 for advanced brain and solid tumors
This Phase 1 trial tests KH617, a new treatment, in adults with advanced cancers to see if it can be given safely and whether it shows signs of benefit. It is especially focused on tumors that have few or no standard treatment options, including certain brain tumor recurrences.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07615348RecruitingPhase 2
CD70 imaging to guide treatment breaks in advanced kidney cancer
This trial tests whether a special type of imaging scan (CD70-targeted PET/CT) can help doctors safely pause treatment in patients with advanced kidney cancer who respond well to standard immunotherapy and targeted therapy. The goal is to reduce unnecessary treatment while keeping the cancer controlled.
Nanjing, JiangsuAges 18 years+ - NCT07618078Recruiting
Personalized Cancer Risk Assessment for Nasopharyngeal Cancer
This study helps doctors predict which patients with nasopharyngeal cancer (a cancer of the upper throat) will benefit most from additional chemotherapy after radiation treatment. It uses a special blood test and imaging to create a personalized risk score for each patient.
Beijing, Beijing MunicipalityAges 18–75 - NCT07613424Recruiting
Gene Testing Study for Advanced Lung Cancer
This study collects and analyzes lung cancer tissue samples to understand genetic differences that may help guide future treatment. You'll provide a tissue sample (either from a biopsy or prior surgery), and researchers will study it—no treatment is given in this study.
BeijingAges 18 years+
Hear when a new Liver Cancer (Locally Advanced or Metastatic) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for liver cancer (locally advanced or metastatic)?
- Yes. Clin2 currently lists 5,775 recruiting liver cancer (locally advanced or metastatic) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a liver cancer (locally advanced or metastatic) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a liver cancer (locally advanced or metastatic) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Colorectal Cancer (Locally Advanced or Metastatic)
- Lung Cancer (Locally Advanced or Metastatic)
- Locally Advanced Rectal Cancer
- Locally Advanced Cervical Cancer
- Locally Advanced Breast Cancer
- Locally Advanced or Metastatic Solid Tumors
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.